Participant is able and willing to provide informed consent, or their legal representative is willing to provide informed consent; and
symptoms attributable to COVID-19 started within the past 5 days and ongoing; and
a positive PCR SARS-CoV-2 test; and
aged ≥50 years; or
aged 18–49 years with one of the following known underlying chronic health conditions considered to make them clinically vulnerable:Chronic respiratory disease (including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication). Chronic heart or vascular disease. Chronic kidney disease. Chronic liver disease. Chronic neurological disease (including dementia, stroke and epilepsy). Severe and profound learning disability. Down’s syndrome. Diabetes mellitus (type or type II). Immunosuppression: primary (eg, inherited immune disorders resulting from genetic mutations, usually present at birth and diagnosed in childhood) or secondary due to disease or treatment (eg, sickle cell, HIV, cancer and chemotherapy). Solid organ, bone marrow and stem cell transplant recipients. Morbid obesity (BMI >35). Severe mental illness. Care home resident. Judged by recruiting clinician or research nurse (registered medical practitioner or trained study nurse) to be clinically vulnerable.
| Age ≥12 years; and
positive PCR test; and
at highest risk of getting seriously ill. This includes some people who have:Down’s syndrome. A rare condition affecting the brain or nerves (including multiple sclerosis, motor neuron disease, Huntington’s disease or myasthenia gravis). Sickle cell disease Certain types of cancer. HIV or AIDS. A severe liver condition (such as cirrhosis). Chronic kidney disease stage 4 or 5. Had an organ transplant. Certain autoimmune or inflammatory conditions (such as rheumatoid arthritis or inflammatory bowel disease). A condition or treatment that makes you more likely to get infections. Had certain types of chemotherapy in the last 12 months. Had radiotherapy in the last 6 months.
A doctor or specialist will confirm if you are eligible for treatment. | Non-hospitalised adults with mild or moderate COVID-19 were eligible.
Key inclusion criteria at randomisation were:SARS-CoV-2 infection that had been laboratory confirmed no more than 5 days earlier. Onset of signs or symptoms no more than 5 days earlier. At least one sign or symptom of COVID-19 and
At least one risk factor for development of severe illness from COVID-19:Age >60 years. Active cancer. Chronic kidney disease. Chronic obstructive pulmonary disease. Obesity, defined by a BMI ≥30. Serious heart conditions (heart failure, coronary artery disease or cardiomyopathies). Diabetes mellitus.
|
| PANORAMIC exclusion criteria | | MOVe-OUT exclusion criteria |
Patient currently admitted to hospital (inpatient). Previous randomisation in the PANORAMIC trial. Currently participating in a clinical trial of a therapeutic agent for acute COVID-19. Additional exclusions specific to each intervention arm, if any, as listed in the Intervention Specific Appendice of currently open trial arms.
| | An anticipated need for hospitalisation for COVID-19 within the next 48 hours. dialysis or estimated glomerular filtration rate less than 30 mL per minute per 1.73 m2. Pregnancy. Unwillingness to use contraception during the intervention period and for at least 4 days after completion of the regimen severe neutropenia (absolute neutrophil count of <500 per millilitre). Platelet count below 100 000 per microlitre. SARS-CoV-2 vaccination.
|